David Vesole, MD
Medical Oncology · Hackensack, NJNPI 1790773356
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $572,840 of the $725,836 with a category attached, or 78.9%. 22 manufacturers reported payments, led by Johnson & Johnson at 30.6% of the total. Reporting peaked in 2022 at $159,662 and has fallen 85.2% since, to $23,608 in 2025. Among medical oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $1146.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$222K
- Takeda Pharmaceuticals U.S.A., Inc.$132K
- GSK$101K
- Amgen$93K
- Sanofi$75K
- Karyopharm Therapeutics Inc.$50K
- plus $53K from 16 others
Across 238 payments — averaging $10,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.3M
- Sanofi$312K
- Amgen$254K
- Janssen Research & Development, LLC$152K
- GSK$86K
- Ichnos Glenmark Innovation Inc$85K
- plus $221K from 8 others
What the payments were for
- Consulting fees$85,22312%
- Speaking & faculty fees$572,84079%
- Grants$1,1810%
- Travel & lodging$55,9248%
- Food & beverage$10,4571%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 265 | $221,831 |
| Takeda Pharmaceuticals U.S.A., Inc. | 84 | $132,142 |
| GSK | 44 | $101,095 |
| Amgen | 77 | $92,665 |
| Sanofi | 54 | $74,827 |
| Karyopharm Therapeutics Inc. | 34 | $50,380 |
| E.r. Squibb & Sons, L.L.C. | 14 | $23,916 |
| Bristol Myers Squibb | 28 | $12,796 |
| Pfizer | 5 | $6,164 |
| Omeros Corporation | 1 | $3,800 |
| Secura Bio, Inc. | 2 | $3,352 |
| Janssen Scientific Affairs, LLC | 2 | $1,260 |
| Menarini Silicon Biosystems, Inc. | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Legend Biotech USA Inc. | 3 | $235 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $172 |
| Novartis | 3 | $73 |
| Sanofi-aventis U.S. LLC | 2 | $63 |
| AbbVie | 3 | $52 |
| Incyte Corporation | 1 | $26 |
| Astellas Pharma US Inc | 1 | $20 |
| Gilead | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$725,836 in reported general payments places this provider in the 95th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 50 | $956,914 |
| RevlimidLenalidomide | 55 | $854,404 |
| Lenalidomide | 15 | $163,994 |
| EliquisApixaban | 12 | $10,143 |
| ValacyclovirValacyclovir Hcl | 41 | $1,775 |
| Dexamethasone | 71 | $1,022 |
| Gabapentin | 17 | $506 |
| Acyclovir | 31 | $472 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 35 | $136 |
| Tramadol Hcl | 14 | $79 |
| Alprazolam | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $23,916 | $956,91450 claims |
| Bristol Myers SquibbRevlimid | $12,796 | $854,40455 claims |
| PfizerEliquis | $6,164 | $10,14312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
- Andrew IpHackensack$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.